Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New registry study aims to sharpen sepsis treatment with ARTICE®

NCT ID NCT07388628

First seen Feb 05, 2026 · Last updated May 18, 2026 · Updated 10 times

Summary

This study follows 200 adults with sepsis or septic shock who are receiving ARTICE® therapy in the ICU. Researchers will track changes in organ function, lab results, and recovery times to better understand how well the treatment works and who benefits most. The goal is to improve care for critically ill patients with immune system failure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEPSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Klinikum Magdeburg, Klinik für Intensiv- und Rettungsmedizin

    RECRUITING

    Magdeburg, 39130, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.